NeuroXess raises ¥700 million Series B for brain-computer interfaces
SDIC Juli, Shenzhen Capital Group and Triwise Capital co-led the financing for clinical trials, manufacturing and product development.
NeuroXess has completed a CNY700 million Series B co-led by SDIC Juli, Shenzhen Capital Group and Triwise Capital, alongside other institutional and returning investors.
The company will fund multicentre clinical trials and registration work for its implantable brain-computer interface system, scale manufacturing and develop its next generation of products.
NeuroXess builds flexible interfaces that decode neural activity for communication and device control. Its development programme includes motor, language and visual applications, as well as integration with AI tools.
Use of funds
Multicentre clinical trials and regulatory registration
Manufacturing scale-up
Next-generation brain-computer interface R&D